image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 0.0308
0 %
$ 503 K
Market Cap
None
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one STSS stock under the worst case scenario is HIDDEN Compared to the current market price of 0.0308 USD, Sharps Technology, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one STSS stock under the base case scenario is HIDDEN Compared to the current market price of 0.0308 USD, Sharps Technology, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one STSS stock under the best case scenario is HIDDEN Compared to the current market price of 0.0308 USD, Sharps Technology, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart STSS

image
$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5$0.0$0.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-9.63 M OPERATING INCOME
4.94%
-9.3 M NET INCOME
5.54%
-6.93 M OPERATING CASH FLOW
18.55%
-1.16 M INVESTING CASH FLOW
-66.57%
5.91 M FINANCING CASH FLOW
-26.43%
0 REVENUE
0.00%
-3.85 M OPERATING INCOME
-90.87%
-4.53 M NET INCOME
-168.62%
-1.76 M OPERATING CASH FLOW
-6.93%
-93.5 K INVESTING CASH FLOW
-85.83%
199 K FINANCING CASH FLOW
-92.71%
Balance Sheet Sharps Technology, Inc.
image
Current Assets 3.17 M
Cash & Short-Term Investments 864 K
Receivables 102 K
Other Current Assets 2.21 M
Non-Current Assets 4.14 M
Long-Term Investments 0
PP&E 4.04 M
Other Non-Current Assets 105 K
11.81 %30.18 %55.17 %Total Assets$7.3m
Current Liabilities 5.19 M
Accounts Payable 977 K
Short-Term Debt 3.76 M
Other Current Liabilities 445 K
Non-Current Liabilities 132 K
Long-Term Debt 0
Other Non-Current Liabilities 132 K
18.36 %70.78 %8.38 %Total Liabilities$5.3m
EFFICIENCY
Earnings Waterfall Sharps Technology, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 9.63 M
Operating Income -9.63 M
Other Expenses -331 K
Net Income -9.3 M
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)(10m)(10m)000(10m)(10m)331k(9m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-465.71% ROE
-465.71%
-127.11% ROA
-127.11%
-162.87% ROIC
-162.87%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sharps Technology, Inc.
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)(10m)(10m)202020202021202120222022202320232024202420252025
Net Income -9.3 M
Depreciation & Amortization 774 K
Capital Expenditures -139 K
Stock-Based Compensation 521 K
Change in Working Capital 0
Others 1.1 M
Free Cash Flow -7.07 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sharps Technology, Inc.
image
STSS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Sharps Technology, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
10.8 K USD 1
0-3 MONTHS
20.1 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on March 28, 2025 NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: STSS) (the “Company” or “Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company's proposal before the shareholder meeting, which is scheduled to be held on March 28, 2025, at 10:00 a.m. Eastern Time. globenewswire.com - 1 month ago
Sharps Technology's CEO Issues Corporate Update Highlighting Agreements for SecureGard and SoloGard and Revenue Developments from Manufacturing Operations in Hungary Company is strategically positioned following the recent $20 million capital raise, enhancing manufacturing capabilities to accelerate qualification and shipments under existing agreements Company is strategically positioned following the recent $20 million capital raise, enhancing manufacturing capabilities to accelerate qualification and shipments under existing agreements globenewswire.com - 1 month ago
Sharps Technology, Inc. Announces Closing of Upsized $20.0 Million Underwritten Public Offering NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The offering closed on January 29, 2025. globenewswire.com - 3 months ago
Sharps Technology's CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and SoloGard Product Supply and Revenue NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, issues a shareholder letter from Robert Hayes, the Company's Chief Executive Officer. globenewswire.com - 4 months ago
Sharps Regains Nasdaq Listing Compliance NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market (“Nasdaq”) that the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market, as set forth in Nasdaq Listing Rule 5550(a)(2) as of November 5, 2024. globenewswire.com - 5 months ago
Sharps Technology, Inc. Announces Stockholders' Approval of Reverse Stock Split Ratio and Effective Date NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc.  (NASDAQ: “STSS” and “STSSW”) ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it will effect a one-for-22 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on October 15, 2024 at 11:59 PM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Sharps has requested that its Common Stock begin trading on October 16, 2024, on a post-reverse split basis on the Nasdaq under the existing symbol "STSS". globenewswire.com - 6 months ago
Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on October 7, 2024 NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company's proposal before the shareholder meeting scheduled to be held on October 7, 2024 at 10:00 a.m. Eastern Time. globenewswire.com - 7 months ago
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS) NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS). About Sharps Technology, Inc. Sharps Technology, Inc., a medical device company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States. accesswire.com - 7 months ago
Sharps Technology, Inc. Closes $3.5 Million Bridge Financing NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million. globenewswire.com - 7 months ago
Sharps Technology, Inc. Announces $3.5 Million Bridge Financing NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into definitive agreements with institutional investors for a secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million. globenewswire.com - 7 months ago
Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders' Meeting NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, announced today that the Company has secured approval from The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) to maintain its listing, subject to conditions outlined below. globenewswire.com - 7 months ago
Sharps Technology CEO Urges Shareholders to Vote in Support of the Three Proposals by the July 12 Voting Deadline Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company's continued growth. globenewswire.com - 9 months ago
8. Profile Summary

Sharps Technology, Inc. STSS

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 503 K
Dividend Yield 0.00%
Description Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
Contact 105 Maxess Road, Melville, NY, 11747 https://sharpstechnology.com
IPO Date April 14, 2022
Employees 55
Officers Mr. Frank Parrado Corporate Controller Mr. Andrew R. Crescenzo CPA Chief Financial Officer Mr. Robert M. Hayes Chief Executive Officer & Director Mr. Ben Scheu Senior Director of Sales